The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

BACKGROUND: The EGFR-T790M mutation is clinically detected using re-biopsy in approximately 50% of patients with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) who harbor EGFR mutations. However, little is...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Yamada, Tadaaki, Okura, Naoko, Takeda, Takayuki, Furutani, Wataru, Kubota, Yutaka, Shiotsu, Shinsuke, Hiranuma, Osamu, Nishioka, Naoya, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288862/
https://www.ncbi.nlm.nih.gov/pubmed/30537950
http://dx.doi.org/10.1186/s12885-018-5153-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288862/
https://www.ncbi.nlm.nih.gov/pubmed/30537950
http://dx.doi.org/10.1186/s12885-018-5153-4

Ejemplares similares